Drug intelligence / Profile preview

Prostowin

Development stage: Unknown
Lead developer: Bal Pharma
Modality: Small Molecules
Administration: Oral

Overview

Prostowin is a proprietary Ayurvedic medicine developed by Bal Pharma (specifically its Bal Vedics division) for the management of benign prostatic hyperplasia (BPH). The formulation is a polyherbal blend of ten ingredients, including extracts from *Mimosa pudica*, *Tribulus terrestris*, and *Areca catechu*. Its therapeutic effect is attributed to a dual mechanism: the inhibition of 5-alpha reductase (primarily via beta-sitosterol and *Areca catechu*), which prevents the conversion of testosterone to dihydrotestosterone (DHT), and alpha-adrenergic blockade (via *Areca catechu*). These actions help reduce prostate volume and alleviate lower urinary tract symptoms such as frequency, urgency, and painful urination.

Brand names: Prostowin
Other names: Prostowin Capsule

Targets

SRD5A (Steroid 5-alpha-reductase)ADRA1A (α1A)

Beyond the preview

Go deeper on Prostowin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostowin.

Explore the full profile